Program
mosunetuzumab
Also written as “Mosunetuzumab”, “Mosunetuzumab (IV)” and “Mosunetuzumab (SC)”.
Its studies are mostly in Lymphoma, Follicular · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lupus Nephritis, led by 2 companies.
Drug pageMosunetuzumab: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 137 open or running | phase 3since Jan 13, 2021 | Jul 14, 2015 | Jul 31, 2027phase 2 · NCT05207670 |
| Ipsen | 10 open or running | phase 2since Dec 29, 2021 | Dec 29, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ipsen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named mosunetuzumabINNProposed as its International Nonproprietary Name in WHO's List 117
- Dec 29, 2021First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT05205252 · United States
TargetBeta
“T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
The one study Ipsen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05205252Hematologic Neoplasms · United States | 2 | Withdrawn | Jul 5, 2023 | 0 |
How it is read
Names in the registry
- “Mosunetuzumab”, 8 entries
- “Mosunetuzumab (IV)”, 2 entries
- “Mosunetuzumab (SC)”, 2 entries
- “Mosunetuzumab (Cohorts A-C)”, 1 entry
- “Mosunetuzumab (Cohorts D-E)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 3 studies
- Lymphoma, B-Cell, 3 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.